Search results
Results from the WOW.Com Content Network
This "formally initiates the litigation process under the Hatch-Waxman Act and triggers a 30-month stay of any potential FDA approval for Sun Pharma's ANDA," Mayne Pharma said in a statement.
Sun Pharmaceutical Industries Ltd. was established by Dilip Shanghvi in 1983 in Calcutta, West Bengal with five psychiatry products and a two-person marketing team. Today it is ranked number one in share of prescriptions with 12 classes of doctors in India and a market leader in Psychiatry, Neurology, Cardiology, Orthopaedics, Gastroenterology, Nephrology, Diabetology, Dermatology, Urology ...
This is an accepted version of this page This is the latest accepted revision, reviewed on 15 November 2024. Indian Businessman Dilip Shanghvi Born (1955-10-01) 1 October 1955 (age 69) Amreli, Gujarat, India Alma mater Bhawanipur Education Society College, University of Calcutta Occupation(s) Founder and MD of Sun Pharmaceuticals Spouse Vibha Shanghvi Children 2 Dilip Shanghvi (born 1 October ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
Get breaking Business News and the latest corporate happenings from AOL. From analysts' forecasts to crude oil updates to everything impacting the stock market, it can all be found here.
Sun Pharma and Taro Announce Termination of Proposed Transaction HAWTHORNE, N.Y. & MUMBAI, India--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYS: TARO) ("Taro") and Sun Pharmaceutical ...
DUSA Pharmaceuticals, Inc., owned by Sun Pharma, is a pharmaceutical company with dermatology products, including Levulan and Nicomide. In the first quarter of 2006, DUSA Pharmaceuticals obtained Sirius Laboratories in a merger estimated to be worth 30 million dollars.
In 2010, Sun Pharmaceuticals of India acquired a majority stake in the company. [6] On 22 March 2012, the company's shares were re-listed on the NYSE. In 2013, Sun Pharmaceuticals attempted to buy the remaining shares in the company (it owns 69% stake), but as the company's financial performance improved, shareholders rejected the offer and the company remained publicly listed.